anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a method for the preparation ofpolymer-fibrous material pre-impregnated with polymer (prepreg).By it the fibres are covered by powder containing at least onepolymer, optionally, an agent initiating the polymerizationreaction. Solvent is added to the composition produced which candissolve the polymer but would not initiate its polymerization.Subsequently the  solvent is evaporated. It is also possible thatthe polymer should first be dissolved in a solvent. Then thefibres get in contact with the produced solution and the solventis evaporated, preferably their surfaces whould be pretreated inorder to facilitate the sticking of the polymer. The fibrestreated in this way are covered by powder polymer. The inventionalso relates to a new material, to method for the preparation of afibres-reinforced composite based on polymer prestrssed fibrousproduct, to new composites and to their aplication.16 claim, 3 figures
BACKGROUND: Sepsis is a severe condition characterized by acute organ dysfunction resulting from an imbalanced host immune response to infections. Apolipoprotein H (APOH) is a critical plasma protein that plays a crucial role in regulating various biological processes. However, the precise role of APOH in the immunopathology of paediatric sepsis remains unclear.
METHODS: In this study, we evaluated the concentration of APOH in paediatric patients with sepsis and healthy individuals. In an experimental sepsis model of caecal ligation and puncture (CLP), the impact of APOH on survival, organ injury, and inflammation was measured. Furthermore, the anti-inflammatory effects of APOH were investigated across diverse immune cell types, encompassing peripheral blood mononuclear cells (PBMCs), peritoneal macrophages (PMs), bone marrow-derived macrophages (BMDMs), and RAW 264.7 macrophages.
RESULTS: In the pilot cohort, the relative abundance of APOH was found to be decreased in patients with sepsis (2.94 ± 0.61) compared to healthy controls (1.13 ± 0.84) (p < 0.001), non-survivors had lower levels of APOH (0.50 ± 0.37) compared to survivors (1.45 ± 0.83) (p < 0.05). In the validation cohort, the serum concentration of APOH was significantly decreased in patients with sepsis (202.0 ± 22.5 ng/ml) compared to healthy controls (409.5 ± 182.9 ng/ml) (p < 0.0001). The application of recombinant APOH protein as a therapeutic intervention significantly lowered the mortality rate, mitigated organ injury, and suppressed inflammation in mice with severe sepsis. In contrast, neutralizing APOH with an anti-APOH monoclonal antibody increased the mortality rate, exacerbated organ injury, and intensified inflammation in mice with non-severe sepsis. Intriguingly, APOH exhibited minimal effects on the bacterial burden, neutrophil, and macrophage counts in the sepsis mouse model, along with negligible effects on bacterial phagocytosis and killing during Pseudomonas aeruginosa infection in PMs, RAW 264.7 cells, and PBMCs. Mechanistic investigations in PMs and RAW 264.7 cells revealed that APOH inhibited M1 polarization in macrophages by suppressing toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) signalling pathway.
CONCLUSION: This proof-of-concept study demonstrated that APOH has a protective role in the host defense response to sepsis, highlighting the potential therapeutic value of APOH in sepsis treatment.
There is a recent paper suggesting that general anesthesia with the EzT is feasible and by no means worse than anesthesia with a conventional ETT, and there is little but growing evidence that narcosis with this SAD can be continued during general anesthesia. This brings up several potential benefits: The larger balloons of the EzT are less traumatic to the mucosal tissue compared to a conventional ETT or to a laryngeal mask. Since the insertion of the EzT can be performed without using a laryngoscope, this also reduces tissue damage and tooth injuries caused by a laryngoscope. Also, It has been demonstrated that a similar SAD - the Combitube - can be placed by anesthesiologists with relatively little formal training and that ventilation during elective surgery is feasible. However, such detailed data are missing for the EzT, with only smaller, monocenter-studies available. The next logical step was therefore to systematically evaluate the EzT beyond its purpose as a rescue device in a prospective, randomized multicenter-study to evaluate the use of the EzT in comparison with the ETT during general anesthesia.

Methods 400 patients with ASA status I-II scheduled for elective surgery in 4 centers were randomized to either the EzT group (n=200) or the ETT group (n=200).
Implantable material testing devices and method of testing materials in an animals are provided. In one embodiment, a method of testing a material in an animal includes associating the material with a retention frame to form a testing device. The retention frame movable between a first shape suited for insertion through a deployment instrument and a second shape suited for retention in the animal. The testing device is inserted in the first shape into the deployment instrument and is driven through the deployment instrument into the animal. Once in the animal, the testing device is permitted to assume the second shape so that the testing device is retained in the animal for a testing period. The testing device is removed from the animal after the testing period is complete, and the material is analyzed. The material may be analyzed for biofilm formation, encrustation, or degradation. The animal also may be analyzed for infection or other reactions to the material. Tissue may be collected from the animal, and the tissue may be analyzed. The testing period may be between about 1 day and about 90 days.
BACKGROUND: Patients with hidradenitis suppurativa (HS) often suffer from comorbid diabetes, metabolic syndrome, and hyperlipidemia and, therefore, are susceptible to the development of cardiovascular diseases (CVDs). Moreover, systemic inflammation plays a vital role in the development of atherosclerosis. The creation of atherosclerotic plaque is characterized by endothelial dysfunction driven by elevated concentrations of interleukin (IL)-1, IL-6, and IL-18 among others, as well as tumor necrosis factor (TNF) alpha.
METHODS: This study aimed to assess the risk of HS patients developing CVDs. We performed a large-scale, propensity-matched global retrospective cohort study analyzing the risk of development of CVDs in patients suffering from HS. The analysis included 144,100 HS patients with 144,100 healthy controls (HC). The cohorts were matched regarding demographics and history of diseases relevant to CVDs, e.g., diabetes, obesity, and nicotine dependence. A total of 90 cardiovascular disorders were identified. The identification of cardiovascular disorders was based on ≥1% appearance of the event, based on absolute numbers, in both cohorts.
RESULTS: Before the matching, HS patients displayed a higher frequency in excess weight or obesity (25 vs. 14.4%, respectively), nicotine dependence, and diabetes mellitus, but lower odds of primary hypertension in comparison to healthy controls. A total of 47 CVDs are associated with an increased risk of onset in HS patients. Although the highest hazard ratio (HR; 2.1; 95% CI: 1.95-2.269) was found for unspecified heart failure, the HS cohort was exceptionally predisposed to developing myocardial infarction (HR: 2.06; 95% CI: 1.88-2.27) and an acute embolism and deep vein thrombosis of the lower extremity (HR: 1.93; 95% CI: 1.74-2.14).
CONCLUSIONS: This is the most extensive study on the association of HS with CVDs. We demonstrated that HS patients are at significantly greater risk of developing various CVDs compared to matched controls, with heart failure being the most common one.
This is a single-arm, Simon 2-stage, phase 2 clinical study conducted in subjects with advanced or metastatic colorectal cancer who have received ≥1 prior line of systemic therapies and are resistant to EGFR inhibitor (cetuximab or panitumumab). Fresh tumor tissue is needed for the MET testing, thus a biopsy will be required to participate in this trial. In a minor percentage of subjects archival tumor tissue could be acceptable for this analysis.Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks. The overall treatment period will be divided into continuous 28 days cycles without treatment interruption. Disease status and tumor response will be assessed per modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 at screening (within 4 weeks before the first scheduled dose of study drug), in 8 weeks intervals while the subjects are on treatment or as clinically indicated until progression of disease, withdrawal of consent, death, or lost to follow-up. Tumor measurement will also be performed during the end of treatment visit if not done within the previous 8 weeks. Subjects with progressive disease at any time during the treatment period will discontinue study treatment. Subjects with stable disease (SD), complete response (CR) and partial response (PR) will stay on treatment until disease progression and/or unacceptable toxicity and/or withdrawal of consent is documented. CR and PR must be confirmed no sooner than 4 weeks after the initial observation. After discontinuation from study treatment during the follow-up period, survival status will be obtained by phone every 3 months until the subject dies, withdraws consent from study, or is lost to follow-up, for a maximum of 12 months.
This is group that will receive the attention bias modification intervention that is programmed to train attention to positive stimuli 100% of the time. Both groups will receive the preceding 3-day brief mindfulness training.
The invention relates to the field of nuclear medicine and molecular imaging, in particular to a dual-targeting compound and a preparation method and application thereof. The structure of the dual targeting compound is shown as the following formula (I). The invention also provides a dual targeting compound which can be labeled by the radioactive nuclide, and the structure of the dual targeting compound is shown as the following formula (I-1) or formula (I-2). The double targeting compound of the invention is used for FAP target and integrin alpha  v  β  3  The targets have higher affinity, and can cooperatively target FAP target and integrin alpha in tumor  v  β  3  The target shows higher tumor uptake and tumor retention time. The invention also provides a radionuclide-labeled dual-targeting compound based on the dual-targeting compound, a preparation method thereof and application of the dual-targeting compound in preparation of FAP and/or integrin alpha for diagnosis or treatment  v  β  3  Use in the manufacture of a medicament for the treatment of a disease characterized by overexpression. （I） Formula (I-1) Formula (I-2).
IPI-504 is a novel, water-soluble analog of 17-AAG and a potent inhibitor of Hsp90. Hsp90's role in the cell is to control the proper folding, function, and viability of various "client" proteins. Many of these client proteins (such as AKT, Her-2, Bcr-Abl, PDGFR-α, and c-Kit) are oncoproteins or important cell signaling proteins. Inhibition of HSP-90 leads to the proteasomal degradation of these proteins.

In patients with HRPC,there are several proteins that are important in the progression of HRPC, including AR, AKT and Her-2. All of these are client proteins of Hsp90 and in response to Hsp90 inhibition are degraded by their proteasome. Preclinical studies have shown that Hsp90 inhibition causes a dose dependent degradation of these client proteins and growth inhibition of prostate cancer in xenograft tumors.
INTRODUCTION: The illusions of head motion induced by galvanic vestibular stimulation (GVS) can be used to compromise flight performance of pilots in fixed-base simulators. However, the stimuli used in the majority of studies fail to mimic disorientation in realistic flight because they are independent from the simulated aircraft motion. This study investigated the potential of bilateral-bipolar GVS coupled to aircraft roll in a fixed-base simulator to mimic vestibular spatial disorientation illusions, specifically the "post-roll illusion" observed during flight.METHODS: There were 14 nonpilot subjects exposed to roll stimuli in a flight simulator operating in a fixed-base mode. GVS was delivered via carbon rubber electrodes on the mastoid processes. The electrical stimulus was driven by the high-pass filtered aircraft roll rate to mimic the semicircular canals' physiological response. The post-roll test scenarios excluded outside visual cues or instruments and required subjects to actively maintain a constant bank angle after an abrupt stop following a passive prolonged roll maneuver. The anticipated outcome was an overshot in roll elicited by the GVS signal.RESULTS: The responses across subjects showed large variability, with less than a third aligning with the post-roll illusion. Subjective ratings suggest that the high-pass filtered GVS stimuli were mild and did not induce a clear sense of roll direction. However, uncontrolled head movements during stimulation might have obscured the intended effects of GVS-evoked illusory head movements.CONCLUSION: The mild and transient GVS stimuli used in this study, together with the uncontrolled head movements, did not convincingly mimic the post-roll illusion.Houben MMJ, Stuldreher IV, Forbes PA, Groen EL. Using galvanic vestibular stimulation to induce post-roll illusion in a fixed-base flight simulator. Aerosp Med Hum Perform. 2024; 95(2):84-92.
PURPOSE: Anti-obesity polypeptides are provided, thereby the formation of an adipose tissue can be inhibited. Therefore, obesity can be inhibited. CONSTITUTION: An anti-obesity polypeptide having the 101 amino acids sequence of SEQ ID NO: 1, a pharmaceutically acceptable salt thereof, and a gene encoding the anti-obesity polypeptide having the nucleotide sequence of SEQ ID NO: 4 are provided. An anti-obesity polypeptide having the 86 amino acids sequence from the N-terminal of SEQ ID NO: 2, a pharmaceutically acceptable salt thereof, and a gene encoding the anti-obesity polypeptide having the nucleotide sequence of SEQ ID NO: 5 are provided. An anti-obesity polypeptides having 71 amino acids sequence from the N-terminal of SEQ ID NO: 3, a pharmaceutically acceptable salt thereof, and a gene encoding the anti-obesity polypeptide having the nucleotide sequence of SEQ ID NO: 6 are provided. The recombinant vector containing the above genes of SEQ ID NOs: 4, 5 and 6 are pcDNA3.0 SynLeptin-1 and -2 or pGEX4T SynLeptin-1 and -2 respectively.
The present invention relates to a sheet-type mask pack and, more specifically, to a sheet-type mask pack which is impregnated with a cosmetic liquid to be attached to the entire surface of the face and is stored in wrapping paper. According to the present invention, the sheet-type mask pack comprises: a left sheet body having a shape corresponding to the left side of the face and having a cut part corresponding to the midline of the face; and a right sheet body having a shape corresponding to the right side of the face and having a cut part corresponding to the midline of the face. A nose attachment part is provided at a position corresponding to the nose in the left sheet body, and a first protrusion protruding to the right beyond the midline to have a shape corresponding to the nose of a wearer is formed on the nose attachment part. A nose attachment part is provided at a position corresponding to the nose in the right sheet body, and a second protrusion protruding to the left beyond the midline to have a shape corresponding to the nose of the wearer is formed on the nose attachment part. The left sheet body and the right sheet body are stacked on each other in wrapping paper. Accordingly, a wearer can separate the stacked left and right sheet bodies by picking up the first protrusion and the second protrusion.
BACKGROUND: Prostate adenocarcinoma (PRAD) is the second leading cause of cancer-related deaths in men. High variability in DNA methylation and a high rate of large genomic rearrangements are often observed in PRAD.
RESULTS: To investigate the reasons for such high variance, we integrated DNA methylation, RNA-seq, and copy number alterations datasets from The Cancer Genome Atlas (TCGA), focusing on PRAD, and employed weighted gene co-expression network analysis (WGCNA). Our results show that only single cluster of co-expressed genes is associated with genomic and epigenomic instability. Within this cluster, TP63 and TRIM29 are key transcription regulators and are downregulated in PRAD. We discovered that TP63 regulates the level of enhancer methylation in prostate basal epithelial cells. TRIM29 forms a complex with TP63 and together regulates the expression of genes specific to the prostate basal epithelium. In addition, TRIM29 binds DNA repair proteins and prevents the formation of the TMPRSS2:ERG gene fusion typically observed in PRAD.
CONCLUSION: Our study demonstrates that TRIM29 and TP63 are important regulators in maintaining the identity of the basal epithelium under physiological conditions. Furthermore, we uncover the role of TRIM29 in PRAD development.
INTRODUCTION: The nature, intensity, and progression of acute pain after bilateral orthotopic lung transplantation (BOLT) performed via a clamshell incision has not been well investigated. We aimed to describe acute pain after clamshell incisions using pain trajectories for the study cohort, in addition to stratifying patients into separate pain trajectory groups and investigating their association with donor and recipient perioperative variables.
METHODS: After obtaining IRB approval, we retrospectively included all patients ≥18 years old who underwent primary BOLT via clamshell incision at a single center between January 1, 2017, and June 30, 2022. We modeled the overall pain trajectory using pain scores collected over the first seven postoperative days and identified separate pain trajectory classes via latent class analysis.
RESULTS: Three hundred one adult patients were included in the final analysis. Three separate pain trajectory groups were identified, with most patients (72.8%) belonging to a well-controlled, stable pain trajectory. Uncontrolled pain was either observed in the early postoperative period (10%), or in the late postoperative period (17.3%). Late postoperative peaking trajectory patients were younger (p = .008), and sicker with a higher lung allocation score (p = .005), receiving preoperative mechanical ventilation (p < .001), or VV-ECMO support (p < .001).
CONCLUSION: Despite the extensive nature of a clamshell incision, most pain trajectories in BOLT patients had a well-controlled stable pain profile. The benign nature of pain profiles in our patient population may be attributed to the routine institutional practice of early thoracic epidural analgesia for BOLT patients unless contraindicated.
Full-incision double-eyelid blepharoplasty is effective, but postoperative complications, such as local trauma and persistent tissue swelling, are major concerns. Because tissue swelling is caused by the obstruction of blood and lymphatic flow, the authors modified the conventional full-incision method to minimize the trauma as much as possible. Twenty-five patients underwent the modified procedure. There was minor swelling immediately after the surgery, which subsided 1 to 5 days after the surgery. No patient reported loss of the double eyelid crease. Only 2 patients underwent a second operation because of a low crease. Satisfactory results were obtained in 92% of patients (23 of 25). According to our understanding of this technique, less trauma is the key to obtaining better results under certain conditions.
PURPOSE:To obtain a remedy for diabetes, containing a crude drug essence extracted from a specific crude drug as an active ingredient. CONSTITUTION:A remedy for diabetes obtained by boiling a crude drug prepared by blending 8-18pts.wt. Glechoma herderacea L. (Glechomae Herba) with 3-8 pts.wt. Houttuynia cordata Thunb. (Houttuyniae Herba), 4-8pts.wt. Dioscorea japonica (Dioscorea Radix) or 2-4.5pts.wt. Dioscorea japonica and 2-4.5pts.wt. Coix lacryma-jobi L. var. ma-yuen Stapf in blending with 400-625pts.wt. water while heating, evaporating and concentrating the leachate while leaching active ingredients of the crude drug into hot water until the amount of the above- mentioned water reduced to almost half and containing the resultant concentrated solution as an active ingredient. Examples of the dosage form include solution, powder, granule, pill, tablet, capsule, etc. An excipient containing starch and lactose added thereto is particularly preferred as the excipient.
Prepn. and use in therapy and diagnostic use and ovular cell extracts having a haploid chromosome set from corpuscular and high molecular fractions (nucleic) acids, proteins, lipides and polysaccharides) and their degradation products, for aiding cell-proliferation and treating sterility and fertility. Antibody-sera against fractions with X- or Y-chromosomes can be used for sex-determination. Cells from fish are esp. suitable as starting materials. In example, for an antibody-serum against bovine Y-chromosomes cell-nuclei are obtained by grinding oval cells from trout-roe in liquid N2, centrifuging in a saccharose-gradient, freeze-drying and decomposing chemically. Antibody serum from rabbits immunised with the oval product is incubated with bull-sperm. The non-agglutinated sperm-cells are isolated and the nuclei from the spermatozoa with Y-chromosomes used for the active immunisation of rabbits or sheep.
Induction placebo enema for the first week of treatment followed by once weekly administration of 15 capsules of study placebo (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study placebo, study subjects on placebo who DO NOT demonstrate improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks, beginning with a FMT induction enema followed by 7 weeks of weekly FMT capsule administration.
The invention relates to a citrus extract bacteriostat, a production process and an application thereof. The citrus extract bacteriostat comprises 0.010-0.02% of citrus extract, 0.003% of pennyroyal and the balance of distilled water. The total acidity of the citrus extract bacteriostat is 0.002-0.020%, and the pH value is 3.2-5.0. The production process comprises the following steps: a, proportioning; b, thoroughly mixing the citrus extract; c, evenly mixing with the distilled water, and regulating the pH value to 3.2-5.0; d, evenly mixing with the pennyroyal; and e, weighing and filtering. The pH value and the total acidity of the citrus extract bacteriostat are regulated to form different application modes, such as skin bacteriostat, gynecological bacteriostat, air and environment purificant, oral bacteriostat and disinfectant. By using the pure natural citrus extract, the citrus extract bacteriostat has the advantages of broad-spectrum antibiosis, strong power, high efficiency, safety and no toxicity. The invention adopts the concept of disinfection in a harmless way, has easy manufacture, fills market vacancy, satisfies great market demands and has more infinite development prospects.